Washburn W K, Bradley J, Cosimi A B, Freeman R B, Hull D, Jenkins R L, Lewis W D, Lorber M I, Schweizer R T, Vacanti J P, Rohrer R J
Department of Surgery, New England Deaconess Hospital, Boston, Massachusetts, USA.
Transplantation. 1996 Jan 27;61(2):235-9. doi: 10.1097/00007890-199601270-00013.
Liver transplantation for patients requiring life-support results in the lowest survival and highest costs. A ten year (1983-1993) regional experience with liver transplantation for critically ill patients was undertaken to ascertain the fate of several subgroups of patients. Of the 828 liver transplants performed at six transplant centers within the region over this period, 168 (20%) were done in patients who met today's criteria for a United Network of Organ Sharing (UNOS) status 1 (emergency) liver transplant candidate. Recipients were classified according to chronicity of disease and transplant number (primary-acute, primary-chronic, reTx-acute, reTx-chronic). Overall one-year survival was 50% for all status 1 recipients. The primary-acute subgroup (n = 63) experienced a 57% one-year survival compared with 50% for the primary-chronic (n = 51) subgroup (P = 0.07). Of the reTx-acute recipients (n = 43), 44% were alive at one year in comparison with 20% for the reTx-chronic (n = 11) group (P = 0.18). There was no significant difference in survival for the following: transplant center, blood group compatibility with donors, age, preservation solution, or graft size. For patients retransplanted for acute reasons (primary graft nonfunction (PGNF) or hepatic artery thrombosis [HAT]), survival was significantly better if a second donor was found within 3 days of relisting (52% vs. 20%; P = 0.012). Over the study period progressively fewer donor organs came from outside the region. No strong survival-based argument can be made for separating, in allocation priority, acute and chronic disease patients facing the first transplant as a status 1 recipient. Clearly patients suffering from PGNF or HAT do far better if retransplanted within 3 days. Establishing an even higher status for recipients with PGNF, perhaps drawing from a supraregional donor pool, would allow surgeons to accept more marginal donors, thus potentially expanding the pool, without significantly compromising patient survival. Retransplantation of the recipient with a chronically failing graft who deteriorates to the point of needing life-support is nearly futile, and in today's health care climate, not an optimal use of scarce donor livers.
对需要生命支持的患者进行肝移植,其生存率最低且成本最高。我们对一个地区十年(1983 - 1993年)间对重症患者进行肝移植的经验进行了研究,以确定几个患者亚组的预后情况。在此期间,该地区六个移植中心共进行了828例肝移植手术,其中168例(20%)是为符合当今器官共享联合网络(UNOS)1级(紧急)肝移植候选标准的患者进行的。接受者根据疾病的慢性程度和移植次数进行分类(初次急性、初次慢性、再次移植急性、再次移植慢性)。所有1级接受者的总体一年生存率为50%。初次急性亚组(n = 63)的一年生存率为57%,而初次慢性亚组(n = 51)为50%(P = 0.07)。再次移植急性接受者(n = 43)中,44%在一年时存活,而再次移植慢性组(n = 11)为20%(P = 0.18)。以下因素在生存率方面无显著差异:移植中心、与供体的血型相容性、年龄、保存液或移植物大小。对于因急性原因(原发性移植物无功能[PGNF]或肝动脉血栓形成[HAT])而再次移植的患者,如果在重新列入名单后3天内找到第二个供体,生存率会显著提高(52%对20%;P = 0.012)。在研究期间,来自该地区以外的供体器官逐渐减少。对于作为1级接受者面临首次移植的急性和慢性疾病患者,在分配优先级上进行区分,无法基于生存率提出有力论据。显然,患有PGNF或HAT的患者如果在3天内进行再次移植,情况会好得多。为患有PGNF的接受者设立更高的优先级,或许从超地区供体库获取供体,将使外科医生能够接受更多边缘供体,从而有可能扩大供体库,而不会显著影响患者生存率。对慢性移植失败且病情恶化到需要生命支持的接受者进行再次移植几乎是徒劳的,在当今的医疗环境下,这并非对稀缺供体肝脏的最佳利用。